Bioquark Inc.   Report issue

For profit Phase 1
Founded: Philadelphia PA United States (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2017
NCT02742857
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

autologous mesenchymal stem cells (1 trial)

bq-a peptide extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Death (Phase 1)

Brain Injuries (Phase 1)

Brain Injuries, Traumatic (Phase 1)

Death (Phase 1)

Diffuse Axonal Injury (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2